1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug

Rivals Novartis and Amgen are already in Phase III with Lp(a) drugs

 
• By Jessica Merrill

The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.

race
Silence is further behind Novartis and Amgen to develop a drug to treat Lp(a). • Source: Shutterstock

An advancing area of cardiovascular-focused drug development – targeting lipoprotein(a), or Lp(a), to reduce risk of atherosclerotic cardiovascular disease (ASCVD) – is shaping up to be a competitive one dominated by big pharmas, and siRNA developer Silence Therapeutics plc would welcome a larger partner to advance its Lp(a) program zerlasiran into Phase III.

Key Takeaways
  • Silence therapeutics reported positive Phase II data for its Lp(a) program zerlasiran.
  • The category is shaping up to be a competitive one with bigger players, Novartis...

That said, CEO Craig Tooman said the company is prepared to move zerlasiran forward independently.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.